Screener
Acadia Pharmaceuticals ACAD Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Daybue | $124.83M+29.9% | $101.14M+19.6% | $109.63M+13.3% | $101.1M+10.8% | $96.09M+13.6% | |
| Nuplazid | $183.13M+8.7% | $166.92M+4.5% | $174.36M+7.1% | $177.53M+11.5% | $168.48M+7.0% |
FAQ
- How does Acadia Pharmaceuticals break its business down?
- Acadia Pharmaceuticals (ACAD) reports revenue by product across 2 parts — Daybue and Nuplazid. Each is extracted from the segment footnotes and tracked over time.
- Where does Acadia Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Acadia Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
